Lisata Therapeutics Files Q1 2025 10-Q
Ticker: LSTA · Form: 10-Q · Filed: May 8, 2025 · CIK: 320017
Sentiment: neutral
Topics: 10-Q, financials, pharmaceutical
Related Tickers: LSTA
TL;DR
Lisata Therapeutics (LSTA) filed its Q1 2025 10-Q. Financials are in.
AI Summary
Lisata Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Caladrius Biosciences, Inc. and NeoStem, Inc., is based in Basking Ridge, NJ. The filing details financial information and business operations for the first quarter of 2025.
Why It Matters
This filing provides investors and stakeholders with the latest financial performance and operational updates for Lisata Therapeutics, Inc. as of March 31, 2025.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Lisata Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- LISATA THERAPEUTICS, INC. (company) — Filer
- CALADRIUS BIOSCIENCES, INC. (company) — Former company name
- NeoStem, Inc. (company) — Former company name
- 20250331 (date) — Period of report
- 20250508 (date) — Filing date
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20250331, meaning the filing covers the period ending March 31, 2025.
What were Lisata Therapeutics' former company names?
Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc. and prior to that, NeoStem, Inc.
Where is Lisata Therapeutics, Inc. located?
The company's business and mail address is 110 Allen Road, Second Floor, Basking Ridge, NJ 07920.
When was this 10-Q form filed?
This 10-Q form was filed on 20250508.
What is the Standard Industrial Classification for Lisata Therapeutics, Inc.?
The Standard Industrial Classification is Pharmaceutical Preparations [2834].
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding LISATA THERAPEUTICS, INC. (LSTA).